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Conclusion Our results indicate that mito-T protects mice 
against DOX-induced cardiotoxicity.
Keywords Doxorubicin · Cardiotoxicity · Mitochondria · 
Mito-TEMPO
Introduction
Doxorubicin (DOX) is an anthracycline chemotherapeutic 
that is widely used for the treatment of many human tumors 
since the late 1960s [1]. Its discovery represented one of 
the great advancements in the fight against cancer; how-
ever, the development of adverse drug reactions, in particu-
lar cardiotoxicity, has limited its use [2].
Although DOX-induced cardiac toxicity appears to be 
multifactorial, the most thoroughly investigated hypothesis 
has been the formation of reactive oxygen species (ROS) 
and there is evidence pointing to cardiac mitochondria as 
primary targets of the toxicity of DOX [3]. The quinone 
moiety of DOX may form semiquinone radicals by one-
electron reduction. This semiquinone, in the presence of 
molecular oxygen, results in the formation of superoxide 
anion and other ROS. Furthermore, it has been reported 
that DOX shows a high affinity for cardiolipin, a phospho-
lipid in the inner mitochondrial membrane, which results in 
their accumulation inside cardiac cells and oxidative dam-
age [4].
The possibility that cardiac dysfunction may lead to con-
gestive heart failure stimulates the development of strate-
gies to prevent or reduce DOX cardiotoxicity in the clinic, 
and the use of antioxidants could be an important strategy 
[5].
The mito-TEMPO (mito-T) is a nitroxide conju-
gated with a triphenylphosphonium (TPP) moiety that is 
Abstract 
Purpose Doxorubicin (DOX) is a chemotherapeutic that 
is widely used for the treatment of many human tumors. 
However, the development of cardiotoxicity has limited its 
use. The aim of the present study was to evaluate the possi-
ble efficacy of mito-TEMPO (mito-T) as a protective agent 
against DOX-induced cardiotoxicity in mice.
Methods C57BL/6 mice were treated twice with mito-
T at low (5 mg/kg body weight) or high (20 mg/kg body 
weight) dose and once with DOX (24 mg/kg body weight) 
or saline (0.1 mL/20 g body weight) by means of intraperi-
toneal injections. The levels of malondialdehyde (MLDA), 
a marker of lipid peroxidation, and serum levels of creatine 
kinase were evaluated 48 h after the injection of DOX.
Results DOX induced lipid peroxidation in heart mito-
chondria (p < 0.001), and DOX-treated mice receiv-
ing mito-T at low dose had levels of MLDA significantly 
lower than the mice that received only DOX (p < 0.01). 
Furthermore, administration of mito-T alone did not cause 
any significant changes from control values. Additionally, 
DOX-treated mice treated with mito-T at high dose showed 
decrease in serum levels of total CK compared to mice 
treated with DOX alone (p < 0.05).
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mitochondria-targeted and have been used as antioxidant. 
Since nitroxides are known to be superoxide dismutase 
(SOD)-mimetics, mito-T may act as a mitochondrial super-
oxide scavenger and to protect mitochondria from the 
DOX-induced oxidative damage [6]. Recent studies docu-
mented that mito-T decreased mitochondrial superoxide 
levels and increased survival rate from septic mice [7], 
attenuated TNF-α-induced mitochondrial ROS and apopto-
sis in H9c2 cells [8] and blocked mitochondrial ROS gen-
eration and reduced DOX-induced platelet apoptosis [9].
Thus, as DOX produces significant amounts of ROS and 
has affinity for mitochondria, inducing mitochondrial and 
cardiac oxidative damage, the aim of the present study was 
to evaluate the possible efficacy of mito-T as a protective 
agent against DOX-induced cardiotoxicity in mice.
Materials and methods
Animals and ethical approval
Six- to ten-week-old female C57BL/6 mice were obtained 
and maintained at the animal facilities at the Gonçalo 
Moniz Research Center-FIOCRUZ (Salvador, Bahia, 
Brazil). The animals received balanced feed and water 
ad libitum.
The current work was carried out in accordance with the 
Brazilian Federal Law on Animal Experimentation (Law 
11794) (http://www.planalto.gov.br/ccivil_03/_ato2007-
2010/2008/lei/l11794.htm). The protocol was approved by 
the Ethics Committee for the Use of Animals in Research 
(CPqGM-FIOCRUZ, CEUA, license number 019/2012).
Design of the work
Seven to eight mice from each group were treated twice 
with mito-T (Fig. 1; Sigma-Aldrich Chemical Co, St. 
Louis, MO, USA) at low (5 mg/kg body weight) or high 
(20 mg/kg body weight) dose and once with DOX (Glen-
mark Farmacêutica Ltda, São Paulo, SP, Brazil; 24 mg/
kg body weight) or saline (Farmace, Barbalha, CE, Bra-
zil; 0.1 mL/20 g body weight) by means of intraperitoneal 
injections, as described below. The mice were euthanized 
48 h after DOX by carbon dioxide inhalation.
Low dose of mito-T:
Group 1—Saline and saline;
Group 2—mito-T (5 mg/kg) twice, 48 and 24 h before 
saline;
Group 3—mito-T (5 mg/kg) twice, 48 and 24 h before 
DOX (24 mg/kg);
Group 4—DOX (24 mg/kg).
High dose of mito-T:
Group 1—Saline and saline;
Group 2—mito-T (20 mg/kg) twice, 24 and 1 h before 
saline;
Group 3—mito-T (20 mg/kg) twice, 24 and 1 h before 
DOX (24 mg/kg);
Group 4—DOX (24 mg/kg).
Determination of lipid peroxidation in heart 
mitochondria
Hearts of animals treated with low dose of mito-T were col-
lected and mitochondria obtained as described by Fernán-
dez-Vizarra et al. [10]. Heart mitochondria lipid peroxida-
tion was quantified by measuring the thiobarbituric acid 
reactive substance, malondialdehyde (MLDA). An aliquot 
of heart mitochondria suspension (100 μL) was incubated 
with 185 μL of a solution containing acetic acid (Sigma-
Aldrich) 50 % in water, 1.3 % thiobarbituric acid (Merck 
KGaA, Darmstadt, HES, Germany) and phosphate buffer 
solution, pH 7.2, in proportion 1:1.5:1.2, respectively, for 
30 min at 90 °C. After that, the samples were centrifuged 
(9000g for 10 min at 4 °C) and the supernatants collected 
for measurement of absorbance at 532 nm using a multi-
plate reader (SpectraMax, Molecular Devices, Sunnyvale, 
CA, USA). Malondialdehyde (Sigma-Aldrich) was used as 
a standard.
Quantification of serum creatine kinase
Blood samples of animals treated with high dose of mito-T 
were taken and centrifuged at 1200g for 20 min at 4 °C. 
Serum was collected and quantified for total creatine kinase 
(CK) and CK-MB using diagnostic kits (Gold Analisa 
Diagnóstica Ltda, Belo Horizonte, MG, Brazil), following 
the manufacturer’s recommendations.
Statistical analysis
The normality of the data was assessed by the D’Agostino 
and Pearson normality test. Statistical differences were 
Fig. 1  Chemical structure of mito-TEMPO (C29H35N2O2P·Cl)
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analyzed using Kruskal–Wallis test followed by Dunn’s 
test. Statistical significance was accepted at p ≤ 0.05. All 
analysis was performed using the GraphPad Prism 5.0 Soft-
ware (San Diego, CA, USA).
Results
DOX induced lipid peroxidation in heart mitochondria 
(p < 0.001), and DOX-treated mice receiving mito-T at low 
dose showed level of MLDA significantly lower compared 
to DOX group (p < 0.01). Furthermore, administration of 
mito-T alone did not cause any significant change from 
control values (Fig. 2).
Additionally, the mice treated with mito-T at high dose 
showed decrease in serum levels of total CK compared to 
DOX alone (p < 0.05). Although not significantly, the levels 
of CK-MB were reduced compared to DOX-treated group 
(Fig. 3). No differences were seen between mito-T-injected 
and mito-T-untreated mice in the low-dose mito-T experi-
ment (data not shown).
Discussion
The search to new substances and therapeutic strategies 
to attenuate chemotherapy toxicity continues. As the car-
diac susceptibility to DOX-induced oxidative stress has 
been associated with the high oxidative metabolism of the 
heart and its lower level of antioxidant enzymes and with 
the affinity of DOX to cardiolipin [11, 12], in the present 
investigation it was evaluated whether mito-T pretreatment 
could produce cardioprotective effects in mice treated with 
DOX.
Pretreatment of animals with mito-T (5 mg/kg, 48 and 
24 h prior to DOX) significantly reduced the lipid peroxi-
dation of heart mitochondria (p < 0.01) indicating targeting 
of the antioxidant to the mitochondria, as referred by Dika-
lova et al. [6]. Lipid peroxidation is considered a good car-
diotoxicity indicator for DOX [4]; therefore, their reduction 
indicates that mito-T probably acts as an antioxidant that 
could prevent the mitochondrial disfunction DOX induced 
and its consequently cardiotoxicity.
Increase in CK serum level after DOX administration 
is referred as a consequence of heart injury [13]. Pretreat-
ment with mito-T (20 mg/kg) twice, 24 and 1 h before 
Fig. 2  Lipid peroxidation in heart mitochondria of mice treated with 
two mito-TEMPO (mito-T; 5 mg/kg body weight) doses and/or once 
with doxorubicin (DOX; 24 mg/kg body weight). Mice were treated 
intraperitoneally with mito-T, 48 and 24 h before administration of 
DOX. Heart mitochondria lipid peroxidation was quantified by meas-
uring the malondialdehyde (MLDA). Negative control mice received 
only saline. Each symbol represents the result obtained from a sin-
gle animal. Horizontal lines represent the median values for groups 
of eight animals. Comparisons among groups were performed by 
Dunn’s multiple comparison test. *p < 0.05; ***p < 0.001
Fig. 3  Serum levels of creatine kinase (CK) total (a) and CK-MB 
(b) in heart of mice treated with two mito-TEMPO (mito-T; 20 mg/
kg body weight) doses and/or once with doxorubicin (DOX; 24 mg/
kg body weight). Mice were treated intraperitoneally with mito-T, 24 
and 1 h before administration of DOX. Each symbol represents the 
result obtained from a single animal. Horizontal lines represent the 
median values for groups of seven or eight animals. Comparisons 
among groups were performed by Dunn’s multiple comparison test. 
*p < 0.05; **p < 0.01
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DOX treatment, inhibited the increase in CK total serum 
level (p < 0.05) induced by DOX. No significant differ-
ences were observed in CK-MB serum levels, however, 
probably because of great variation within groups. In work 
evaluating different doses of mito-T, Patil et al. [7] sug-
gest that accumulation of higher dose of mito-T within the 
mitochondria could depolarize membrane and impair their 
protector effect. Thus, the therapeutic effects of this anti-
oxidant at high dose should be better investigated.
Conclusion
Our data suggest that mito-T at a relatively high dose pro-
tects mice against DOX-induced cardiotoxicity; however, 
as the precise mechanism of the antioxidant activity of 
mito-T remains unclear, further investigations are required 
to confirm this assumption.
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